Ardent Health, Inc.

Day range

$12.05 – $12.47

Open

$12.13

Prev close

$12.27

Volume

97.35K

Market cap

$1.73B

Shares out

141.05M

P/E

22.12

P/S

0.27

P/B

1.28

P/FCF

4.66

ROE

5.8%

ROA

1.5%

Debt/Equity

0.82

Div yield

0.00%

As of Oct 23, 2026

• Executive compensation changeOct 23, 2026

  The Company has recharacterized Mr. Bonick's separation as of the Separation Date as a termination for "Cause." As a result of the Board's final determination, the Company will discontinue the remaining severance payments and benefits ... including approximately $4.5 million of unpaid cash severance, and all outstanding unvested performance-based restricted stock units (PRSUs) will be cancelled and/or forfeited.

• Business updateSep 4, 2026

  After giving effect to the removal of such non-GAAP adjustments, the Company's Adjusted EBITDA for the year ended December 31, 2025 decreased from $545.0 million (as previously presented) to $447.3 million, and the Company's Adjusted EBITDAR... decreased from $709.3 million... to $611.6 million.

• Director departureJun 30, 2026

  Martin J. Bonick had departed from his role as President and Chief Executive Officer of the Company and had stepped down from the Company's Board of Directors (the "Board"), effective as of the Effective Date.

• Director departureJun 2, 2026

  Mr. Caspers succeeds Martin J. Bonick, who separated from the Company and stepped down from the Board effective as of the Effective Date.

• Annual meeting resultsMay 26, 2026

  Ardent Health, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Annual Meeting") on May 20, 2026. At the Annual Meeting, a total of 98,778,826 shares of the Company's common stock, out of a total of 143,095,662 shares of common stock outstanding and entitled to vote as of the record date for the Annual Meeting, were represented in person or by proxy. Voting results from the Annual Meeting were as follows: The following 11 director nominees were elected to the Company's Board of Directors, as follows: Mark Sotir, Martin J. Bonick, Peter Bulgarelli, Peter Bynoe, Suzanne Campion, Robert A. DeMichiei, William Goodyear, Ellen Havdala, Edmondo Robinson, Rahul Sen, Rob Webb.

Days to cover

10.7

Short interest

4.63M

Avg volume

432.63K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Is the Options Market Predicting a Spike in Ardent Health Stock?
  neutralZacks Investment Research· Sep 16, 2026
• Is Ardent Health Stock a Buy After a Director Purchased More Than 11,000 Shares?
  positiveThe Motley Fool· Jun 12, 2026
• ARDENT HEALTH FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Ardent Health, Inc. Stockholders to Contact the Firm Before March 9th Regarding Their Rights
  negativeGlobeNewswire Inc.· Mar 8, 2026
• Bronstein, Gewirtz & Grossman LLC Urges Ardent Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
  negativeGlobeNewswire Inc.· Mar 8, 2026
• EDR IMPORTANT DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Endeavor Group Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 18 Deadline in Securities Class Action - EDR
  negativeGlobeNewswire Inc.· Mar 8, 2026